Taking Control of Your Lung Cancer Journey
Receiving a lung cancer diagnosis can feel overwhelming, but having the right genetic information empowers you and your medical team to make informed treatment decisions. The OncoPro NCCN Lung Cancer Panel with PD-L1 Test represents a significant advancement in personalised cancer care, providing comprehensive biomarker analysis that guides targeted therapy selection.
What This Test Reveals About Your Cancer
This sophisticated genetic panel examines 11 crucial biomarkers that determine how your lung cancer may respond to different treatments. The test analyses:
- EGFR, ALK, ROS1, RET, and NTRK1 – Genetic mutations that may respond to targeted therapies
- KRAS and BRAF – Common mutations affecting treatment response
- MET and ERBB2 – Additional biomarkers with targeted treatment options
- MSI – Microsatellite instability indicating potential for immunotherapy
- PD-L1 – Crucial biomarker for immunotherapy eligibility and response prediction
Who Should Consider This Comprehensive Testing
This test is particularly valuable for:
- Patients newly diagnosed with non-small cell lung cancer (NSCLC)
- Individuals whose lung cancer has returned after previous treatment
- Patients considering immunotherapy or targeted therapy options
- Those wanting to avoid unnecessary chemotherapy side effects
- Individuals seeking the most current, evidence-based treatment guidance
Why Comprehensive Biomarker Testing Matters
Understanding your cancer’s genetic profile can significantly impact your treatment journey:
- Personalised Treatment Plans – Match your specific cancer mutations with targeted therapies
- Avoid Ineffective Treatments – Prevent wasting time on therapies unlikely to work
- Reduce Side Effects – Targeted therapies often have fewer side effects than traditional chemotherapy
- Access to Advanced Treatments – Identify eligibility for cutting-edge immunotherapies
- Peace of Mind – Know you’re pursuing the most scientifically informed treatment path
Understanding Your Results with Confidence
Your results will provide clear, actionable information that your oncologist will discuss with you in detail. The report identifies specific genetic mutations and biomarkers, along with treatment recommendations based on the latest NCCN guidelines. This comprehensive analysis helps answer critical questions about which treatments are most likely to be effective for your particular cancer type.
Investment in Your Health Journey
| Test Option | Price | Turnaround Time |
|---|---|---|
| Regular Price | ZAR 52,000 | 35 Working Days |
| Special Price | ZAR 46,800 | 35 Working Days |
Consider this test as an investment in targeted, effective treatment that could save you from costly, ineffective therapies and unnecessary side effects.
Nationwide Trust and Accessibility
Oracle Genomics brings advanced genetic testing to patients across South Africa, with trusted services available in Johannesburg, Cape Town, Durban, Pretoria, and nationwide. Our partnership with leading oncologists ensures that your results are interpreted by specialists who understand the latest treatment advancements.
Take the Next Step in Your Treatment Journey
Don’t leave your treatment decisions to chance. Comprehensive genetic testing provides the clarity needed for effective, personalised cancer care. Contact Oracle Genomics today to schedule your OncoPro NCCN Lung Cancer Panel with PD-L1 Test and take control of your treatment path with confidence and scientific precision.
Ready to get the answers you need? Book your test consultation today and start your journey toward personalised, effective lung cancer treatment.
